Please ensure Javascript is enabled for purposes of website accessibility

Why Arcus Biosciences Stock Is On Fire Today

By George Budwell – Nov 18, 2021 at 8:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.

What happened

Shares of Arcus Biosciences (RCUS -3.09%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead Sciences (GILD -0.44%) has decided to exercise its options for Arcus' two anti-TIGIT molecules, domvanalimab and AB308, as well as for the adenosine receptor antagonist etrumadenant and the small molecule CD73 inhibitor quemliclustat.

Arcus will pocket a healthy $725 million as a result of this option exercise on the part of Gilead. Additionally, the two companies announced that they will co-develop and share the global costs associated with these oncology programs. 

An upward pointing trendline drawn in white chalk on a bluish-green chalkboard.

Image source: Getty Images.

So what

This updated partnership agreement will give Gilead the flexibility to explore a variety of novel anti-cancer combination therapies in the clinic. In its press release, for example, the biotech noted that it plans on assessing potential combo therapies consisting of Arcus' various pipeline candidates and its potent antibody–drug conjugate sacituzumab govitecan-hziy (brand name: Trodelvy).

What's important to understand from an investing perspective is that this deal could prove to be a significant milestone in the biotech giant's quest to move beyond infectious diseases as its main value driver. Gilead has long wanted to pivot toward oncology due to the long-lived nature of these therapies in the marketplace.    

Now what

Why didn't Gilead simply buy Acrus? With a market cap of $2.6 billion at Wednesday's close, Gilead easily could have bought Arcus lock, stock, and barrel. By going the licensing route, the biotech seems to be signaling to shareholders that it no longer has an appetite for risky business development deals. That's not surprising after its pricy Kite Pharma acquisition a few years back. Gilead, in effect, is clearly taking a far more cautious approach to pipeline development these days, which is a great sign for shareholders. That being said, Gilead could still pull the trigger on an Arcus buyout if one or more of these combo therapies bears fruit in the clinic. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.